The Study On Expression Of Adrenomedullin In The Breast Carcinoma And Axillary Lymph Nodes And The Experiment Of Its Intervention Therapy

Breast cancer is the most common type of malignant tumors in women, whose incidence rate has increased gradually in the past few years. In spite of significant advances in surgery and the use of new, more effective radiotherapy, chemotherapeutic and endocrinotheraputic regimens, the overall 5-year survival of patients with breast cancer is about 85%. An improved understanding of the mechanisms regulating the growth of breast cancer cells may eventually lead to the improvement of techniques which facilitates early diagnosis, prediction of the prognosis and determination of the response to therapy. Eventually, it may even be possible to design effective targeted therapies which will work by interfering with the biochemical processes of the growth of breast cancer cells.The growth and progression of tumours is dependent on the process of angiogenesis, which begins when a pinpoint colony of tumour cells expands to a size where simple diffusion of nutrients (and wastes) is insufficient. New capillaries are elicited, and the tumour then enters into a phase at which perfusion becomes the mechanism by which nutrients arrive and metabolic wastes are carried away. Therefore, blood supply is an important factor for the growth and progression of the tumour. A survival method might be the production and secretion of vasodilator substances such as ADM (adrenomedullin) to enhance the availability of nutrient factors to tumour bed. Recently, it has been shown that ADM is a novel growth factor for endothelial cells and is angiogenic in vivo in the chick chorioallantoic membrane assay.Adrenomedullin (ADM) is a hypotensive peptide initially isolated from human pheochromocytoma at 1993. It is a 52-amino-acid peptide belonging to the calcitonin gene peptide superfamily based on its slight homology (24%)...